Neonatal convulsions and subarachnoid hemorrhage after in utero exposure to paroxetine;Convulsiones y hemorragia subaracnoidea tras exposición a paroxetina in utero

Revista de Neurologia

Volumn 36, Issue 8, 2003, Pages 724-726

  Salvia Roiges M D ^a   Garcia, Ll ^b   Gonce Mellgren A ^b   Esque Ruiz M T ^a   Figueras Aloy, J ^a   Carbonell Estrany, X ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antidepressants; Convulsion; Newborn; Paroxetine; SSRI; Subarachnoid haemorrhage selective serotonin reuptake inhibitors

Indexed keywords

ANTIDEPRESSANT AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; BLOOD CLOTTING DISORDER; BRAIN HYPOXIA; BRAIN ISCHEMIA; BRAIN MALFORMATION; CASE REPORT; CONVULSION; DELIVERY; HUMAN; MALE; METABOLIC DISORDER; NEWBORN; NEWBORN INFECTION; PRENATAL DRUG EXPOSURE; RISK ASSESSMENT; SEIZURE THRESHOLD; SUBARACHNOID HEMORRHAGE; SYMPTOMATOLOGY; TERATOGENICITY; THIRD TRIMESTER PREGNANCY; VASCULAR FRAGILITY; WITHDRAWAL SYNDROME;

EID: 0037611122     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3608.2002521     Document Type: Article

References (26)

1. Gunasekara NS, Noble S, Benfield P. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 1998; 55: 85-123.
2. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998; 279: 609-10.
3. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Eng J Med 1996; 335: 1010-5.
4. Dahl ML, Olhager E, Ahlner J. Paroxetine withdrawal syndrome in a neonate. Br J Psychiatry 1997; 171: 391-2.
5. Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal Withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001; 90: 288-91.
6. Ibister GK, Dawson A, Whytee IM, Prior FH, Clancy C, Smith AJ. Neonatal Paroxetine withdrawal syndrome or actually serotonin syndrome? Arch Dis Child Fetal Neonatal Ed 2001; 85: 147-8.
7. Stiskal JA, Kulin N, Koren G, Ho T, Ito S. Neonatal paroxetine withdrawal syndrome. Arch Dis Child Fetal Neonatal Ed 2001; 84: 134-5.
8. Gerola O, Fiocchi S, Rondini G. Antidepressant therapy in pregnancy: A review from the literature and report of suspected paroxetine withdrawal syndrome in a newborn. Rivista Italiana di Pediatria 1999; 25: 216-8.
9. Nijhuis IJ, Kok-Van Rooij GW, Bosschaart AN. Withdrawal reactions of a premature neonate after maternal use of paroxetine. Arch Dis Child Fetal Neonatal Ed 2001; 84: 77.
10. Leyman S, Mattelaer PM, Van Steenberge I. Paroxetine: postmarketing experience on 4024 depressed patients in Belgium. Eur J Clin Res 1995; 7: 287-96.
11. Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TCG, Zussman BD, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 1989; 80: 60-75.
12. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome review. Clin Psychopharmacol 1997; 17: 208-21.
13. Jick SS, Jick H, Knauss TA, Dean AD. Antidepressants and convulsions. J Clin Psychopharmacol 1992; 12: 241-5.
14. Ottervanger JP, Stricker BHC, Huls J, Weeda JN. Bleeding attributed to the intake of paroxetine. Am J Psychiatry 1994; 151: 781-2.
15. Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996; 37: 12-6.
16. Humphries JE, Wheby MS, VandenBerg SR. Fluoxetine and the bleeding time. Arch Pathol Lab Med 1990; 114: 727-8.
17. De Abajo FJ, García-Rodríguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999; 319: 1106-9.
18. Evans TG, Buys SS, Rodgers GM. Acquired abnormalies of platelet function. N Engl J Med 1991; 324: 1671.
19. Calhoun JW, Calhoun DD. Prolonged bleeding time in a patient treated with sertraline. Am J Psychiatry 1996; 153: 443.
20. De Abajo FJ, Jick H, Derby L, Jick S, Schmitz S. Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. Br J Clin Pharmacol. 2000; 50: 43-7.
21. Lesch KP, Wolozin BL, Murphy DL, Reiderer R. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 1993; 60: 2319-22.
22. Sanders-Bush E, Mayer SE. 5-Hydroxytryptamine (serotonin) receptor agonists and antagonists. In Goodman and Gilman's the Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 1996. p. 249-63.
23. Li N, Waller NF, Ladjervadi M, Hjemdahl P. Effects of serotonin on platelet activation in whole blood. Blood Coagul Fibrinolysis 1997; 8: 517-23.
24. Wagner A, Montero D, Martensson B, Siwers B, Asberg M. Effects of fluoxetine treatment of platelet 3H-imipramine binding, 5-HT uptake and 5-HT content in major depressive disorder. J Affect Dis 1990; 20: 101-13.
25. Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ. Fluoxetine and bleeding in obsessive-compulsive disorder. Am J Psychiatry 1991; 148:949.
26. Tielens JAE. Vitamin C for paroxetine and fluvoxamine-associated bleeding. Am J Psychiatry 1997; 153: 883.